Free Trial
OTCMKTS:UCBJF

UCB (UCBJF) Stock Price, News & Analysis

UCB logo
$170.00 -4.30 (-2.47%)
As of 04/4/2025 12:00 PM Eastern

About UCB Stock (OTCMKTS:UCBJF)

Key Stats

Today's Range
$170.00
$170.00
50-Day Range
$170.00
$202.00
52-Week Range
$123.00
$209.66
Volume
25 shs
Average Volume
704 shs
Market Capitalization
$32.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Remove Ads
Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Stock News Headlines

Short Interest in UCB SA (OTCMKTS:UCBJF) Increases By 20.8%
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
UCB price target raised to EUR 220 from EUR 130 at Berenberg
UCB price target raised to EUR 200 from EUR 105 at Morgan Stanley
UCB assumed with an Equal Weight at Morgan Stanley
UCB SA (0NZT) Receives a Hold from Kepler Capital
See More Headlines

UCBJF Stock Analysis - Frequently Asked Questions

UCB's stock was trading at $197.0250 at the beginning of the year. Since then, UCBJF stock has decreased by 13.7% and is now trading at $170.00.
View the best growth stocks for 2025 here
.

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
4/06/2025
Next Earnings (Estimated)
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:UCBJF
Employees
9,083
Year Founded
1928

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.27 billion
Cash Flow
$7.30 per share
Price / Cash Flow
23.28
Book Value
$50.52 per share
Price / Book
3.37

Miscellaneous

Free Float
N/A
Market Cap
$32.13 billion
Optionable
Not Optionable
Beta
0.47

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:UCBJF) was last updated on 4/6/2025 by MarketBeat.com Staff
From Our Partners